Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model

Experimental Neurology

Volumn 219, Issue 1, 2009, Pages 298-307

  Muñoz, Ana ^a,b   Carlsson, Thomas ^a   Tronci, Elisabetta ^a   Kirik, Deniz ^a   Björklund, Anders ^a   Carta, Manolo ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

5 HT1A agonist; 5 HT1B agonist; AIMs; Apomorphine; Dyskinesia; GABA; Glutamate; l DOPA; Parkinson's disease; Serotonin

Indexed keywords

5 PROPOXY 3 (1,2,5,6 TETRAHYDRO 4 PYRIDYL)PYRROLO[3,2 B]PYRIDINE; APOMORPHINE; LEVODOPA; SEROTONIN; SEROTONIN 1 AGONIST; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 1B AGONIST; SEROTONIN 1B RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DYSKINESIA; FEMALE; INNERVATION; LOW DRUG DOSE; NERVE STIMULATION; NONHUMAN; PARKINSON DISEASE; PRESYNAPTIC NERVE; PRIORITY JOURNAL; RAT; SEROTONINERGIC NERVE CELL;

ANIMALS; APOMORPHINE; BRAIN; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; FEMALE; LEVODOPA; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN AGONISTS;

EID: 68549126759     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2009.05.033     Document Type: Article

References (37)

1. Andersson M., Hilbertson A., and Cenci M.A. Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol. Dis. 6 (1999) 461-474
2. Antonelli T., Fuxe K., Tomasini M.C., Bartoszyk G.D., Seyfried C.A., Tanganelli S., and Ferraro L. Effects of Sarizotan on the corticostriatal glutamate pathways. Synapse 58 (2005) 193-199
3. Bara-Jimenez W., Bibbiani F., Morris M.J., Dimitrova T., Sherzai A., Mouradian M.M., and Chase T.N. Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Mov. Disord. 20 (2005) 932-936
4. Bjorklund A., Baumgarten H.G., and Rensch A. 5,7-Dihydroxytryptamine: improvement of its selectivity for serotonin neurons in the CNS by pretreatment with desipramine. J. Neurochem. 24 (1975) 833-835
5. Carey R.J., Depalma G., Damianopoulos E., Muller C.P., and Huston J.P. The 5-HT1A receptor and behavioral stimulation in the rat: effects of 8-OHDPAT on spontaneous and cocaine-induced behavior. Psychopharmacology (Berl) 177 (2004) 46-54
6. Carta M., Stancampiano R., Tronci E., Collu M., Usiello A., Morelli M., and Fadda F. Vitamin A deficiency induces motor impairments and striatal cholinergic dysfunction in rats. Neuroscience 139 (2006) 1163-1172
7. Carta M., Carlsson T., Kirik D., and Bjorklund A. Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in parkinsonian rats. Brain 130 (2007) 1819-1833
8. Ceci A., Baschirotto A., and Borsini F. The inhibitory effect of 8-OH-DPAT on the firing activity of dorsal raphe serotoninergic neurons in rats is attenuated by lesion of the frontal cortex. Neuropharmacology 33 (1994) 709-713
9. Cenci M.A., Whishaw I.Q., and Schallert T. Animal models of neurological deficits: how relevant is the rat?. Nat. Rev., Neurosci. 3 (2002) 574-579
10. Crosby N.J., Deane K.H., and Clarke C.E. Amantadine for dyskinesia in Parkinson's disease. Cochrane Database Syst. Rev. (2003) CD003467
11. Dekundy A., Lundblad M., Danysz W., and Cenci M.A. Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav. Brain Res. 179 (2007) 76-89
12. Dupre K.B., Eskow K.L., Negron G., and Bishop C. The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat. Brain Res. 1158 (2007) 135-143
13. Dupre K.B., Eskow K.L., Barnum C.J., and Bishop C. Striatal 5-HT(1A) receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat. Neuropharmacology 55 (2008) 1321-1328
14. Goetz C.G., Damier P., Hicking C., Laska E., Muller T., Olanow C.W., Rascol O., and Russ H. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov. Disord. 22 (2007) 179-186
15. Goodwin G.M., De Souza R.J., Wood A.J., and Green A.R. The enhancement by lithium of the 5-HT1A mediated serotonin syndrome produced by 8-OH-DPAT in the rat: evidence for a post-synaptic mechanism. Psychopharmacology (Berl). 90 (1986) 488-493
16. Hajos M., Hajos-Korcsok E., and Sharp T. Role of the medial prefrontal cortex in 5-HT1A receptor-induced inhibition of 5-HT neuronal activity in the rat. Br. J. Pharmacol. 126 (1999) 1741-1750
17. Hjorth S., and Sharp T. Effect of the 5-HT1A receptor agonist 8-OH-DPAT on the release of 5-HT in dorsal and median raphe-innervated rat brain regions as measured by in vivo microdialysis. Life Sci. 48 (1991) 1779-1786
18. Hoyer D., Hannon J.P., and Martin G.R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav. 71 (2002) 533-554
19. Iravani M.M., Tayarani-Binazir K., Chu W.B., Jackson M.J., and Jenner P. In MPTP treated primates, the selective 5-HT1a agonist (R)-(+)-8-hydroxy-DPAT inhibits levodopa-induced dyskinesia but only with increased motor disability. J. Pharmacol. Exp. Ther. 319 (2006) 1225-1234
20. Kannari K., Tanaka H., Maeda T., Tomiyama M., Suda T., and Matsunaga M. Reserpine pretreatment prevents increases in extracellular striatal dopamine following l-DOPA administration in rats with nigrostriatal denervation. J. Neurochem. 74 (2000) 263-269
21. Kannari K., Yamato H., Shen H., Tomiyama M., Suda T., and Matsunaga M. Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered l-DOPA in the striatum with nigrostriatal denervation. J. Neurochem. 76 (2001) 1346-1353
22. Knobelman D.A., Kung H.F., and Lucki I. Regulation of extracellular concentrations of 5-hydroxytryptamine (5-HT) in mouse striatum by 5-HT1A and 5-HT1B receptors. J. Phar. Exp. Ther. 292 (2000) 1111-1117
23. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., and Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 15 (2002) 120-132
24. Marin C., Rodriguez-Oroz M.C., and Obeso J.A. Motor complications in Parkinson's disease and the clinical significance of rotational behavior in the rat: have we wasted our time?. Exp. Neurol. 197 (2006) 269-274
25. Marin C., Aguilar E., Rodriguez-Oroz M.C., Bartoszyk G.D., and Obeso J.A. Local administration of Sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats. Psychopharmacology (2009) 10.1007/s00213-00801452-9
26. Matsubara K., Shimizu K., Suno M., Ogawa K., Awaya T., Yamada T., Noda T., Satomi M., Ohtaki K., Chiba K., Tasaki Y., and Shiono H. Tandospirone, a 5-HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions. Brain Res. 1112 (2006) 126-133
27. Mignon L.J., and Wolf W.A. 8-hydroxy-2-(di-n-propylamino)tetralin reduces striatal glutamate in an animal model of Parkinson's disease. NeuroReport 16 (2005) 699-703
28. Muñoz A., Li Q., Gardoni F., Marcello E., Qin C., Carlsson T., Kirik D., Di Luca M., Björklund A., Bezard E., and Carta M. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of l-DOPA-induced dyskinesia. Brain 131 (2008) 3380-3394
29. O'Neill M.F., and Parameswaran T. RU24969-induced behavioural syndrome requires activation of both 5HT1A and 5HT1B receptors. Psychopharmacology (Berl) 132 (1997) 255-260
30. Olanow C.W., Damier P., Goetz C.G., Mueller T., Nutt J., Rascol O., Serbanescu A., Deckers F., and Russ H. Multicenter, open-label, trial of Sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin. Neuropharmacol. 27 (2004) 58-62
31. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1998), Academic Press, San Diego
32. Ravenscroft P., Chalon S., Brotchie J.M., and Crossman A.R. Ropinirole versus l-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia. Exp. Neurol. 185 (2004) 36-46
33. Smith L.M., and Peroutka S.J. Differential effects of 5-hydroxytryptamine1a selective drugs on the 5-HT behavioral syndrome. Pharmacol. Biochem. Behav. 24 (1986) 1513-1519
34. Sporer K.A. The serotonin syndrome. Implicated drugs, pathophysiology and management. Drug Saf. 13 (1995) 94-104
35. Tanaka H., Kannari K., Maeda T., Tomiyama M., Suda T., and Matsunaga M. Role of serotonergic neurons in l-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. NeuroReport 10 (1999) 631-634
36. Yamada J., Sugimoto Y., and Horisaka K. The behavioural effects of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in mice. Eur. J. Pharmacol. 154 (1988) 299-304
37. Zhang X., Andren P.E., Greengard P., and Svenningsson P. Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in l-DOPA treatment of an animal model of Parkinsonism. Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 2163-2168